Результаты поиска

Modular cementless prosthetic reconstruction after resection of lower extremity malignant tumor.

IntroductionThe aim of the study is to report the preliminary clinical and functional outcomes of a modular cementless tumor resection prosthesis system (Megasystem-C®, Waldemar Link GmbH&Co. KG, Hamburg, Germany) in patients undergoing limb salvage surgery with wide resection in a lower extremity primary or metastatic malignant bone tumor.Material and methodsFifty-two consecutive patients (33 male and 19 female; mean age 37.1 years (range, 16 to 79) with primary or metastatic lower extremity malignant bone tumor who underwent wide resection and reconstruction with cementless Megasystem-C® sys

Совпадение в полном тексте источника
… Diagnosis was osteosarcoma in 17, metastatic disease in 11, Ewing sarcoma in 7 patients, giant-cell tumor in 5 patients, chondrosarcoma in 5 patients, multiple myeloma in 3 and liposarcoma, leiomyosarcoma, synovial sarcoma and neurofibrosarcoma in one patient each. … Clinical and radiographic evidence of aseptic loosening 3 | Periprosthetic or prosthetic fracture Non-mechanical | 4 | Infection requiring removal of prosthesis 5 | Recurrence or progression of tumor Table 2 Patient demographics and tumor characteristics. a Including multiple myeloma, liposarcoma, leiomyosarcoma …

The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.

One approach to developing novel anti-cancer agents is to identify and characterise targets that directly regulate cell growth and are dysfunctional in the disease state. One such target is the interaction between the p53 tumour suppressor and the oncogene product of the murine double minute gene, MDM2. MDM2 is known to bind wild-type p53 and block the transcriptional activation of p53-dependent genes. We have previously described a cancer-prone family with elevated levels of wild-type p53, and now show that MDM2 is also over-expressed in the proband from this family. Interestingly, the overex

Cardiac tumors in a tertiary care cancer hospital: clinical features, echocardiographic findings, treatment and outcomes.

Cardiac tumors are a rare entity, comprised of tumors with diverse histology and natural history. We report the clinical characteristics, echocardiograhic findings, therapy and outcome of 59 patients with primary and metastatic cardiac tumors. Our institutional echocardiogram data base from 1993 through 2005 was reviewed to identify patients diagnosed with intra-cardiac tumor. A total of 59 patients with cardiac tumors were identified and included in the study. The patients' characteristics, presenting symptoms, diagnostic tests, location, histology of the tumor, treatment and the one year sur

Совпадение в полном тексте источника
… . | Yes | Yes 14 | 15/M | Undiff. sarcoma pelvis | 0.7×0.8 | RA/RV | I | Sarcoma | Yes | No 15 | 31/F | Endometrial sarcoma | NA | RA | Dyspnea | Sarcoma | Yes | No 16 | 54/F | Leiomyosarcoma (med.) | 3.5×4.1 | RA | I | Leiomyosarcoma | Yes | No 17 | 56/F | Leiomyosarcoma (IVC) | 3.1×2.4 | RA | I | Leiomyosarcoma … Leiomyosarcoma, synovial sarcoma, osteosarcoma, fibrosarcoma, myxoidsarcoma, liposarcoma, mesenchymal sarcoma, neurofibrosarcoma, malignant fibrous histocytoma are other cardiac sarcomas observed. 8 , 15 Angiosarcomas are predominantly found on the right side while osteosarcomas and unclassified sarcomas …

Palliative care of proximal femur metastatic disease and osteolytic lesions: results following surgical and radiation treatment.

BACKGROUND: Femoral bone metastases (FBM) or lesions (FBL) can lead to loss of mobility and independence due to skeletal-related events (SRE), e.g. pain, deformity and pathological fractures. Aim of this study was to analyze effects of radiotherapy and surgery, different surgical techniques and complications on disease-specific survival (DSS). METHODS: Patients who underwent palliative therapy for FBM or FBL between 2014 and 2020 were retrospectively analyzed. Chi-square test was used to detect intergroup differences. Survival was calculated using Kaplan-Meier method, Cox regression and compa

Совпадение в полном тексте источника
… | | 1 (1.7) | 1 (2.3) B-cell lymphoma | 2 (1.3) | 2 (3.8) | | Colon adenocarcinoma | 2 (1.3) | 2 (3.8) | | Hepatocellular carcinoma | 2 (1.3) | | | 2 (4.5) GIST 2 | 1 (0.6) | | | 1 (2.3) Thyroid carcinoma | 1 (0.6) | | | 1 (2.3) Laryngeal squamous cell carcinoma | 1 (0.6) | 1 (1.9) | | Leiomyosarcoma … n = 27) 4 (14.8) 22 (23.2) 1 (11.1) CUP adenocarcinoma ( n = 6) 1 (3.7) 2 (2.1) 3 (33.3) Esophageal carcinoma ( n = 3) 3 (3.2) Colon carcinoma ( n = 1) 1 (9.1) Rectal carcinoma ( n = 3) 3 (3.2) Thyroid carcinoma ( n = 1) 1 (1.1) Laryngeal carcinoma ( n = 1) 1 (1.1) Rhabdomyosarcoma ( n = 2) 2 (2.1) Leiomyosarcoma …

Was Lymphovascular Invasion Associated With Increased Odds of Early Distant Metastasis in Soft Tissue Sarcoma?

BACKGROUND: Soft tissue sarcomas are a heterogeneous group of malignancies with varied clinical outcomes. Existing prognostic calculators do … o 0.73 [95% CI 0.001 to 0.04]; p = 0.04) when adding lymphovascular invasion to the baseline model. Leiomyosarcoma histology (OR 7.44 [95% CI 2.90 to 19.1]; p < 0.001) and positive surgical margins (OR 2.54 [95% CI 1.21 to 5.18]; p = 0.01) were independently associated with higher odds of lymphovascular invasion positivity, but liposarcoma histology decreased th …

Malignant Neoplasms Arising in the Cardiac Pacemaker Cavity: A Systematic Review.

Cancer is the abnormal proliferation of physiologically inadequate cells. Studies have identified the cardiac pacemaker pocket as a site of rare neoplasms. To evaluate the clinical outcomes, treatment, prognosis, and individualized management of tumors originating in the cardiac pacemaker pocket, a systematic review was conducted using case reports and case series available in the PubMed/Medline, Science Direct, Cochrane Central, LILACS, and Scientific Electronic Library Online (Scielo) databases. Pacemaker pocket tumors affected patients with a mean age of 72.9 years, with a higher incidence

Совпадение в полном тексте источника
… Diagnostic patterns of cutaneous leiomyosarcoma [ 30 ], inflammatory myofibroblastic tumors [ 32 ], and malignant fibrous histiocytoma [ 37 ] were also identified by the study in single samples. … Cutaneous leiomyosarcoma developing on a pacemaker pocket. Dermatol. Surg. Off. Publ. Am. Soc. Dermatol. Surg. 2009;35:863–867. doi: 10.1111/j.1524-4725.2009.01145.x. 31. González-Vela M.C., Salcedo W., Neira C., González-López M.A., Ayala H., Val-Bernal J.F. …

An unexpected cause of a swollen pacemaker pocket: a case report.

BACKGROUND: A complication originating from the pacemaker pocket after device implantation can most often be explained by a post-operative pocket haematoma, or, less frequently, by a pocket infection. Both conditions need immediate assessment, dedicated treatment, and specialized follow-up. In rare cases, however, a swollen pacemaker pocket has an alternative diagnosis, which is exemplified by the following case. CASE SUMMARY: A 70-year-old male patient had a-specific symptoms of fatigue, dyspnoea, and coughing for some weeks. He also noted an evident, new swelling of his pacemaker pocket sev

Совпадение в полном тексте источника
… There are case reports and small case series describing metastatic lesions of melanoma, 3 malignant lesions in the proximity of breast carcinoma, 4–6 sarcoma, 7 , 8 rhabdomyosarcoma, 9 cutaneous leiomyosarcoma , 10 squamous cell and basocellular carcinoma of the skin, 11 , 12 non-Hodgkin lymphoma, 13 … Cutaneous leiomyosarcoma developing on a pacemaker pocket. Dermatol Surg 2009;35:863–867. 11. Kang D, Do K, Nattiv J, Zareh M, Doshi R. Malignant transformation of a chronically infected implantable cardioverter-defibrillator pocket. HeartRhythm Case Rep 2018;4:307–309. 12. Reyes CV. …

The management of uterine leiomyomas.

OBJECTIVE: The objective of this document is to serve as a guideline to the investigation and management of uterine leiomyomas. OPTIONS: Th … y words "leiomyoma," "fibroid," "uterine artery embolization," "uterine artery occlusion," "uterine leiomyosarcoma," and "myomectomy." The level of evidence has been determined using the criteria described by the Canadian Task Force on the Periodic Health Examination. BENEFITS, HARMS, AND COSTS: The majority of fibroids are asymptomatic and will not require int …

Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma.

Liposarcoma (LPS) is a common soft tissue sarcoma that encompasses diverse subtypes of well-differentiated/dedifferentiated, myxoid/round cell, and pleomorphic LPS. There is heterogeneity among the various LPS types with regard to prognosis, molecular pathogenesis, and response to treatment. Well-differentiated (WDLPS) and dedifferentiated liposarcoma (DDLPS) are most common types, which share common genetic alteration of chromosome 12q13-15 amplification resulting in amplification of oncogenes, including MDM2 (Mouse double minute 2), CDK4 (cyclin-dependent kinase 4), and HMGA2 (High mobility

Совпадение в полном тексте источника
… Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial . … Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma . …

Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.

Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not si

Совпадение в полном тексте источника
… Activity in heavily pretreated leiomyosarcoma and other STS was also observed [ 28 ]. … Amin-Mansour A , George S , Sioltec S Genomic evolutionary patterns of leiomyosarcoma and liposarcoma . Clin. Cancer Res. 25 ( 16 ), 5135 – 5142 ( 2019 ). 31164371 10.1158/1078-0432.CCR-19-0271 PMC7341441 4. …

A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors.

Non-melanomatous cutaneous spindle cell neoplasms are a rare group of malignancies that present a diagnostic challenge, and for which there is a lack of consensus on how to best manage patients with advanced disease and only limited reports of immune-checkpoint inhibitor (ICI) responses. In this study, we performed a single-center retrospective review of treatment outcomes for all advanced non-melanomatous cutaneous spindle cell neoplasms treated with ICIs. Blinded histopathology reviews occurred to confirm each diagnosis. Comprehensive tumour profiling included whole exome sequencing for tumo

Совпадение в полном тексте источника
… This broad group of tumours can encompass spindle cell squamous cell carcinoma (SpSCC), pleomorphic dermal sarcoma (PDS), desmoplastic melanoma, angiosarcoma, and leiomyosarcoma. Poor biopsies and small excisions often add to the diagnostic difficulties faced by pathologists. … For example, desmoplastic melanoma (a rare variant of malignant melanoma characterised by a spindle cell pattern with stromal fibrosis) is exquisitely sensitive to ICIs, whilst various sarcomas such as leiomyosarcoma are traditionally managed with chemotherapy [ 13 ]. …

Selinexor, a selective inhibitor of nuclear export, shows anti-proliferative and anti-migratory effects on male germ cells in vitro.

BackgroundSelinexor (SLX), a selective inhibitor of nuclear export (SINE), has been shown to interfere with nuclear export mechanisms and to exert antitumor effects in a variety of cancer cell types. It is known to regulate multiple fundamental cellular processes, including the DNA damage response, cell proliferation, and stress signaling pathways. Nevertheless, its potential effects on reproductive cells remain inadequately characterized. The present study was aimed to investigate the cytotoxic, apoptotic, anti-proliferative and anti-migratory effects of SLX on GC1 (spermatogonia) and GC2 (sp

Совпадение в полном тексте источника
… In addition, Nair et al. investigated the cytotoxic effects of SLX in liposarcoma, malignant peripheral nerve sheath cells, dedifferential liposarcoma, uterine leiomyosarcoma, osteosarcoma and synovial tumor cells [ 31 ]. … Preclinical activity of Selinexor in combination with eribulin in uterine leiomyosarcoma. Experimental Hematol Oncol. 2023;12(1):78. 10.1186/s40164-023-00443-w. 45. Zhu ZC, Liu JW, Yang C, Zhao M, Xiong ZQ. …

Antiresorptive medication-related osteonecrosis of the jaw: Incidence and preventive measures utilization in cancer patients.

INTRODUCTION: Antiresorptive drugs are commonly used to treat cancer and bone metastases. These drugs can impose the risk of osteonecrosis of the jaw (ONJ). ONJ is a serious complication that can lead to significant morbidity and mortality. This study aimed to investigate the incidence and preventive measures utilization of ONJ among cancer patients treated with antiresorptive agent. MATERIALS AND METHODS: This retrospective cohort study investigated 210 adult patients with cancer on either zoledronic acid (ZA) or denosumab at a tertiary cancer center. The primary endpoint was to determine th

Совпадение в полном тексте источника
… Other types included malignancies occurring in lung (2.9 %), gastric (1.9 %), nasopharyngeal carcinoma (1.4 %), while renal cell carcinoma, cervical cancer, leiomyosarcoma, gallbladder, hepatocellular carcinoma, uterine and giant cell tumor were reported in 1 patient each (0.5 % each). … Other less common types included renal cell carcinoma, cervical cancer, nasopharyngeal carcinoma, leiomyosarcoma, gallbladder, hepatocellular carcinoma, and uterine cancer (0.47 % each). …

Perspectives of patients, partners, primary and hospital-based health care professionals on living with advanced cancer and systemic treatment.

PurposeAn emerging group of patients lives longer with advanced cancer while receiving systemic treatment. This study aimed to investigate psychosocial aspects of living longer with advanced cancer, and experiences with psychosocial care, from the perspectives of patients, partners, and health care professionals (HCPs).MethodsFrom May to December 2020, participants were purposively selected. In-depth, semi-structured interviews were conducted by video or phone call, containing open questions regarding psychosocial aspects and psychosocial care in oncology. The data was analysed following thema

Совпадение в полном тексте источника
… They had varying advanced cancer diagnoses, including melanoma, gastrointestinal tract cancer, lung cancer, breast cancer, gastrointestinal stromal tumour, leiomyosarcoma and multiple myeloma. Seven partners (four women and three men) with a mean age of 63 (17.8) years participated. … (Male, 73, metastatic leiomyosarcoma) Ongoing uncertainty, fear and hope In describing their emotions, participants often mentioned uncertainty, fear and hope. …

Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment.

Cancer progression and metastasis due to tumor immune evasion and drug resistance is strongly associated with immune suppressive cellular responses, particularly in the case of metastatic tumors. The myeloid cell component plays a key role within the tumor microenvironment (TME) and disrupts both adaptive and innate immune cell responses leading to loss of tumor control. Therefore, strategies to eliminate or modulate the myeloid cell compartment of the TME are increasingly attractive to non-specifically increase anti-tumoral immunity and enhance existing immunotherapies. This review covers cur

Совпадение в полном тексте источника
… Trabectedin is FDA approved for treatment of unresectable or metastatic liposarcoma and leiomyosarcoma ( 115 ) ( Table 3 ). Table 3 US clinical trials using Trabectedin as myeloid cell depleting chemotherapy for cancer. … OS highest group average 416 days | Metastatic Leiomyosarcoma|Metastatic Liposarcoma|Unresectable Leiomyosarcoma|Unresectable Liposarcoma | Drug: Avelumab|Drug: Trabectedin | Phase 1|Phase 2 | 35 6 | NCT03138161 | SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue …

The safety and efficacy of the Stryker OptaBlate™ Bone Tumor Ablation system for vertebral body metastases.

BACKGROUND: Metastatic spinal lesions are a significant cause of morbidity and decreased quality of life in those with a high tumor burden. Despite treatment modalities such as medical therapy (e.g., chemotherapy, steroids), spinal augmentation procedures, and radiation therapy, many patients still experience refractory back pain due to neoplastic infiltration of the vertebral body and/or pathologic compression fractures. With the aim to address refractory pain in patients who have exhausted conventional treatment options, Stryker developed the OptablateTM Bone Tumor Ablation system (BTA; Stry

Совпадение в полном тексте источника
… neoplasm, kappa-restricted; alive at follow-up; back pain resolved | 8 6 | F | 38 | Colorectal adenocarcinoma | Midline lumbar pain with T9/T12 lesions on imaging | T9 and T12 | Died 33 days following procedure; reported immediate decrease in pain postoperatively | 1 week 7 | F | 76 | Retroperitoneal leiomyosarcoma … All patients had vertebral body metastases from a primary neoplastic process, including retroperitoneal leiomyosarcoma, pancreatic adenocarcinoma, prostate adenocarcinoma, invasive ductal carcinoma of the breast, renal cell carcinoma, lung adenocarcinoma, squamous cell carcinoma (SCC) of the oropharynx …

The Rates of Cement Leakage Following Vertebroplasty in Osteoporotic versus Metastatic Disease.

Introduction Percutaneous vertebroplasty is used for symptomatic osteoporotic fractures and osteolytic neoplasms. We performed a retrospective study to analyze the pattern of leaks in the two cohorts. Material and Methods Vertebroplasties performed over a 7-year period at a tertiary orthopaedic center were included in the study and divided into osteoporotic and neoplastic groups. The incidence and pattern of cement leaks in each group were documented and analyzed. Results There were 75 leaks of a cohort of 211 vertebroplasties with a relatively equal proportion in osteoporotic and neoplastic g

Совпадение в полном тексте источника
… Table 1 Total number of leaks, osteoporotic, versus metastatic Groups | Total Cancer cases total | 37 Osteoporotic cases total | 12 Total | 49 The primary sites of metastasis included breast carcinoma ( n = 11), multiple myeloma ( n = 8), cholangiocarcinoma ( n = 1), vascular leiomyosarcoma ( n = 1) … Cancer type | n Breast cancer | 10 Lung cancer | 2 Cholangiocarcinoma | 1 Prostate cancer | 3 Thymic cancer | 1 Vascular leiomyosarcoma | 1 MM | 8 Bladder cancer | 1 Lymphoma | 1 Endometrial | 1 Seminoma | 1 Unknown primary | 4 Renal cell cancer | 3 Total | 37 Cement Leakage Rates Of the total 49 cases …

Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?

Synthetic lethality strategies are likely to be integrated in effective and specific cancer treatments. These strategies combine different specific targets, either in similar or cooperating pathways. Chromatin remodeling underlies, directly or indirectly, all processes of tumor biology. In this context, the combined targeting of proteins associated with different aspects of chromatin remodeling can be exploited to find new alternative targets or to improve treatment for specific individual tumors or patients. There are two major types of proteins, epigenetic modifiers of histones and nuclear o

Совпадение в полном тексте источника
… /Topoisomerase I inhibition | Doxorubicin 4 | EZH2 (KMT6A) | Tazemetostat | Osteosarcoma, leiomyosarcoma cell lines | [ 33 ] DNMT | Azacitidine/Decitabine 5 | DOT1L (KMT4) | Pinometostat (EPZ-5676) | MLL rearrangements | [ 29 ] Topoisomerase I inhibitors, DNA methylation inhibitor | daunorubicin Azacytidine … NSD2 inhibition with tazemetostat or chaetocin, two KMT inhibitors, sensitizes cells to doxorubicin or ionizing radiation in leiomyosarcoma and osteosarcoma cell lines [ 33 ]. SETD2 (KMT3A) exclusively mediates the trimethylation of H3K36 (H3K36me3), a chromatin mark of transcriptional elongation. …

Investigating the Analgesic Mechanisms of Acupuncture for Cancer Pain: Insights From Multimodal Bioelectrical Signal Analysis.

PurposeCancer pain management remains a significant clinical challenge. While acupuncture has shown potential in alleviating cancer pain, its underlying mechanisms are not yet fully understood. This study investigates the neurophysiological mechanisms underlying acupuncture's analgesic effects using multimodal bioelectrical signal analysis.Patients and methodsFifteen cancer pain patients underwent acupuncture while wearing portable, multi-sensor devices to capture bioelectrical signals. Pain levels were assessed using the Numerical Rating Scale (NRS) before and during needle retention. Neuroph

Совпадение в полном тексте источника
… Specifically, these included 1 case of uterine leiomyosarcoma (postoperative pathological stage pT1NxM1 stage IV, with secondary pulmonary malignancy), 1 case of colon cancer, 1 case of sigmoid colon cancer, 1 case of lung cancer, 1 case of pleomorphic undifferentiated sarcoma of the right thigh, 1 case … Included Participants Characteristics | Total sample (n = 15) Sex, No. (%) | Female | 8(53.3) Male | 7(46.7) Age, mean (SD), y | 56.03(0.83) Course of the disease, mean (SD), m | 21.3(15.54) Cancer Types | Gastric cancer (3, 20%); Multiple myeloma (2, 13.3%); Others (10 cases, 66.7%, including 1 uterine leiomyosarcoma …